Sepsis Diagnostics Market size was valued at USD 2.5 billion in 2024 and is likely to exceed USD 10.79 billion by the end of 2037, expanding at over 11.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of sepsis diagnostics is evaluated at USD 2.74 billion.. The growth of the market can be attributed to the increasing number of elderly people who are prone to sepsis. Further, the growing technological advancements in the field of sepsis diagnostics are expected to add to the market growth. The United States Food and Drug Administration, FDA, granted marketing authorization to Immunoexpress Inc.'s SeptiCyte RAPID in December 2021. In October 2021, Prenosis Inc. extended an existing agreement with Roche Diagnostics to accelerate the clinical diagnosis of sepsis. Prenosis, Inc. is a precision diagnostic company that uses AI in order to help diagnose patients more accurately.
In addition to these, factors that are believed to fuel the growth of sepsis diagnostics market include the increase in sepsis cases, the increased burden of hospital-acquired infections, the rising number of pneumonia cases, a higher level of sepsis treatment, and an increase in funding for research related to sepsis. Increased use of sepsis diagnostic products is expected to contribute to market growth. In addition, a new intervention to actively prevent, treat and evaluate sepsis in pregnant women was funded by more than GBP 3 million in June 2021.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
11.8% |
|
Base Year Market Size (2024) |
USD 2.5 billion |
|
Forecast Year Market Size (2037) |
USD 10.79 billion |
|
Regional Scope |
|
Product (Assay Kits & Reagents, Blood Culture Media)
The global market is segmented and analyzed for demand and supply by product into IBS with assay kits & reagents and blood culture media. Out of the two types of sepsis diagnostics, the blood culture media segment is estimated to gain the largest sepsis diagnostics market share of about 42% in the year 2037. The growth of the segment can be attributed to the increasing convenience and cost-effectiveness of this mode of testing. Further, the growing use of blood culture media by hospitals and pathology laboratories is also expected to contribute to the growth of the segment. For instance, it was found that the Sepifast system, which uses PCR techniques, had a better diagnostic performance when compared to blood cultures during an experimental study on patients from Thailand suffering from sepsis. As a result of increasing awareness about health care and the growing number of surgical procedures, it is also noted that instrument segments will continue to grow over the forecast period. For example, in September 2019 Guthrie, a U.S.-based Integrated Health System, started to use Wolters Kluwer Point of Care advisors for detecting and treating Sepsis at four hospitals within the area. All these factors are anticipated to contribute to the growth of the segment.
Technology (Microbiology, Immunoassays, Flow Cytometry)
The global sepsis diagnostics market is also segmented and analyzed for demand and supply by technology into microbiology, immunoassays, and flow cytometry. Amongst these three segments, the microbiology segment is expected to garner a significant share of around 45% in the year 2037. It is based on the fact that microbiological technology makes use of culture media tests to detect and identify sepsis organisms in a precise manner. Moreover, the growing segment is being driven by New Strategic Initiatives undertaken by major players. For instance, in April 2019, BD introduced the new BACTEC plasma quality monitoring media to help identify and reduce sepsis incidence among patients who receive blood transfusions. This, as a result, is anticipated to create numerous opportunities for the growth of the segment in the coming years.
Our in-depth analysis of the global market includes the following segments:
|
By Product |
|
|
By Technology
|
|
|
By Pathogen |
|
|
By Testing Type |
|
North American Market Forecast
The share of sepsis diagnostics market in North America, amongst the market in all the other regions, is projected to be the largest with a share of about 39% by the end of 2037. The growth of the market can be attributed majorly to the increasing and developed healthcare infrastructure in the region. This has led to an increase in the number of advanced diagnostic equipment and programs being used across the region. Furthermore, the sepsis diagnostics market's growth is supported by a high presence of key players and an adequate reimbursement framework across that region. Moreover, demand for new diagnostics solutions is expected to rise due to a high incidence of sepsis and infectious diseases. For instance, according to the Centers for Disease Control and Prevention, in August 2021, approximately 1.7 million adults in America develop sepsis, and nearly 270,000 Americans die due to sepsis. It was also found that 1 in 3 patients who die in a hospital have sepsis. Hence, its diagnosis will increase and the market will grow as a result of the high number of cases in the country. The market will also be supported by increasing investments in research and development to diagnose sepsis. For example, Cytovale Inc., in April 2020, expanded its partnership with the Biomedical Advanced Research and Development Authority, BARDA, to diagnose sepsis in patients with potential respiratory infections, including COVID-19. Research costs are estimated to be US$1.2 billion. 5.9 million.
APAC Market Statistics
The Asia Pacific sepsis diagnostics market is estimated to be the second largest, registering a significant share by the end of 2037. The growth of the market can be attributed majorly to the increasing research efforts by key players in the last few years that have fueled a growing need to rapidly diagnose sepsis. For instance, Cytovale Inc. announced a partnership with the Biomedical Advanced Research and Development Authority, BARDA, for the diagnosis of sepsis in patients with infectious respiratory disease, including COVID-19, in April 2020. In addition to a contribution of 3.83 million by BARDA, the research was expected to amount to US$ 5.9 million. In addition, the region's launch of effective treatments and clinical trials are also anticipated to boost the sepsis diagnostics market growth during the forecast period.
Europe Market Forecast
Further, the sepsis diagnostics market in Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2037. The growth of the market can be attributed majorly to the increasing number of fatalities caused by sepsis in the region. There is a series of trials in order to reduce the number of diseases that have been caused, as well as by applying novel diagnostics and therapeutic approaches. The growing incidence of sepsis, coupled with a rising number of diagnostic laboratories across the country, is driving the market. For instance, the Pasteur Institute, a non-profit foundation dedicated to studying vaccines and diseases reports that the sepsis-related death rate in France is nearly 27%. All these factors contribute to the growth of the market.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?